Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiangfang Baoxin capsule plus conventional therapy for hypertensive cardiac hypertrophy
ChiCTR2300077419Phase 3Completed
- Sponsor
- Wuxi Hospital of Traditional Chinese Medicine
- Start
- May 2022
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of Jiangfang Baoxin in hypertensive heart disease and left ventricular hypertrophy (LVH) (3 arms), sponsored by Wuxi Hospital of Traditional Chinese Medicine. Primary endpoints: blood pressure, serum metabolomics and 1 more. Started May 2022; status: completed.
02
Drugs
Jiangfang Baoxin
03
Conditions
hypertensive heart diseaseleft ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on ChiCTR2300077419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077419.